Recently Added |View All
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of mortality and morbidity worldwide.
A pilot study at Temple suggests that daily use of humidified nasal high-flow (NHF) therapy with an air-oxygen blend as a maintenance therapy could benefit patients discharged from hospital after an acute exacerbation of COPD.
Persistent pulmonary hypertension of the newborn (PPHN, also known as neonatal pulmonary hypertension and persistent fetal circulation syndrome), affects 2% of live births and is a major cause of neonatal mortality.
Gerard J. Criner, MD, FACP, FACCP, outlines the details of the Gala Therapeutics RheSolve Study for treating patients with chronic bronchitis.
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States. Despite optimal pharmacological treatment, many patients with chronic obstructive pulmonary disease remain very disabled.
Pulmonary embolism (PE) is the third most common cardiovascular cause of inpatient hospital death in the United States, and the prevalence of PE risk factors—including surgery, obesity, a sedentary or immobile lifestyle, and advanced age—is ...
Asthma is a global health problem that affects approximately 300 million people in all age and ethnic groups. There is an estimated 250,000 deaths each year related to or resulting from Asthma. Treatment guidelines can be difficult to ...
Gerard Criner, MD, FACP, FACCP, outlines the details of the SPRAY-BC clinical trial for the treatment of chronic bronchiits in patients with COPD.